Intrasense Joins DATATRAK Connect™ Program

                  Intrasense Joins DATATRAK Connect™ Program

PR Newswire

CLEVELAND, June 24, 2013

CLEVELAND, June 24, 2013 /PRNewswire/ --DATATRAK  International, Inc. (OTCQX:
DTRK), a leader in developing cloud-based, unified eClinical® technologies and
delivering related services for the clinical trials industry, today announced
Intrasense (NYSE Alternext: ALINS) became the newest DATATRAK Connect™ Program
member. Intrasense, a global leader in multimodal medical imaging software,
develops and markets Myrian®, an advanced suite of applications for the review
and analysis of medical images and the assessment of drug candidates efficacy
in oncology and other pathologies.

(Logo: )

Patrick Mayette, Intrasense's CEO, said, "We are proud to include DATATRAK in
our international network of leading partners to extend our reach to the
clinical trials market. The seamless combination of our innovative medical
image reading and analysis solutions with DATATRAK's technology will create
additional value to clinical trials professionals."

"As the use of medical images in clinical trials continues to increase,
doctors are seeking access to these images in context with the clinical data
to provide faster, higher quality diagnoses," stated Laurence P. Birch,
DATATRAK's Chairman of the Board and CEO. "Partnering with Intrasense provides
our clients access to advanced imaging technologies and a single source for
collecting, viewing and cleaning clinical trial data. We continue to develop
innovative solutions for accelerating cures."

The DATATRAK Connect™ Partner Program is collaboration between synergic
companies to accelerate the drug development process. The program allows for
extended service offerings to cover all areas of the drug development process
with the goal of reducing study costs and furthering business development

Join DATATRAK Thought Leaders:

  oThe DATATRAK Blog

Tweet: New DATATRAK Connect™ Partner – Intrasense 

About Intrasense
Intrasense, a global leader in medical imaging software solutions, designs,
develops and markets Myrian®, a unique software suite for the visualization
and advanced processing of multimodal medical images (MRI, CT scans, PET,
X-rays, etc.). Developed with leading academic partners, Myrian® combines and
uses all of the various medical images to extract information that is vital to
the patient's care, to the rapid appraisal of the efficacy of treatment and,
therefore, to assessing drug candidates in oncology and other pathologies.
With over 700 client sites around the world, Myrian® has been certified as a
"medical device" in over 40 countries, in the United States (FDA), Europe (CE)
and Asia. Intrasense SA is listed on NYSE Alternext (FR0011179886 – ALINS) and
has offices in 9 countries.

DATATRAK International is a worldwide technology and services company
delivering unified eClinical® solutions and related services for the clinical
trials industry. DATATRAK built its multi-component, comprehensive solution on
a single, unified platform and expanded this concept to include services
delivery via DATATRAK's Clinical and Consulting Services group. The Company
delivers a complete portfolio of software products designed to accelerate the
reporting of clinical research data from sites to sponsors and ultimately
regulatory authorities, faster and more efficiently than loosely integrated
technologies. The DATATRAK ONE™ software solution, deployed worldwide through
an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and
device studies in multiple languages throughout the world. DATATRAK has
offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North
Carolina. For more information, visit

Except for the historical information contained in this press release, the
statements made in this release are forward-looking statements. These
forward-looking statements are made based on management's expectations,
assumptions, estimates and current beliefs concerning the operations, future
results and prospects of the Company and are subject to uncertainties and
factors which are difficult to predict and, in many instances, are beyond the
control of the Company, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements. For a
list of certain factors that may cause actual results to differ materially
from those contemplated in these forward looking statements, please see the
Company's report filed with the OTCQX Market on May 15, 2013 announcing its
results for the first quarter of 2013. The Company undertakes no obligation to
update publicly or revise any forward-looking statement whether as a result of
new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

Contact: Lisa Pahl, Director Marketing, DATATRAK International, Inc.,
+1-979-393-9025Patrick Mayette, CEO, Intrasense SA,
Press spacebar to pause and continue. Press esc to stop.